CN114746107A - 用于预防人腺体遭受放射损伤的方法 - Google Patents

用于预防人腺体遭受放射损伤的方法 Download PDF

Info

Publication number
CN114746107A
CN114746107A CN202080081331.6A CN202080081331A CN114746107A CN 114746107 A CN114746107 A CN 114746107A CN 202080081331 A CN202080081331 A CN 202080081331A CN 114746107 A CN114746107 A CN 114746107A
Authority
CN
China
Prior art keywords
botulinum toxin
gland
anticholinergic
toxin type
psma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080081331.6A
Other languages
English (en)
Chinese (zh)
Inventor
J·米勒
R·鲍姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Treatment Co ltd
Original Assignee
Merz Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Treatment Co ltd filed Critical Merz Treatment Co ltd
Publication of CN114746107A publication Critical patent/CN114746107A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Radiation-Therapy Devices (AREA)
CN202080081331.6A 2019-10-10 2020-10-12 用于预防人腺体遭受放射损伤的方法 Pending CN114746107A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102019215585.5A DE102019215585B4 (de) 2019-10-10 2019-10-10 Verfahren zur prävention von strahlenschäden in humanen drüsen
DE102019215585.5 2019-10-10
PCT/EP2020/078619 WO2021069740A1 (de) 2019-10-10 2020-10-12 Verfahren zur prävention von strahlenschäden in humanen drüsen

Publications (1)

Publication Number Publication Date
CN114746107A true CN114746107A (zh) 2022-07-12

Family

ID=72944110

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080081331.6A Pending CN114746107A (zh) 2019-10-10 2020-10-12 用于预防人腺体遭受放射损伤的方法

Country Status (11)

Country Link
EP (1) EP4021483A1 (de)
JP (1) JP2022552309A (de)
KR (1) KR20220080144A (de)
CN (1) CN114746107A (de)
AU (1) AU2020361545A1 (de)
BR (1) BR112022006877A2 (de)
CA (1) CA3153898A1 (de)
DE (1) DE102019215585B4 (de)
IL (1) IL292125A (de)
MX (1) MX2022004331A (de)
WO (1) WO2021069740A1 (de)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
ATE337011T1 (de) * 2001-02-07 2006-09-15 Beth Israel Hospital Modifizierte psma-liganden und deren verwendung
US20080063732A1 (en) * 2006-07-31 2008-03-13 Hantash Basil M Method of increasing the efficacy of neurotoxin
AU2012209274A1 (en) * 2011-01-24 2013-09-12 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
WO2016014750A1 (en) * 2014-07-23 2016-01-28 Landy Toth Precision chemical ablation and treatment of tissues
CA2959726A1 (en) * 2014-09-08 2016-03-17 Molecular Insight Pharmaceuticals, Inc. Organ protection in psma-targeted radionuclide therapy of prostate cancer
US11383084B2 (en) * 2017-04-27 2022-07-12 Palo Alto Investors Treatment of dermatological conditions via neuromodulation

Also Published As

Publication number Publication date
AU2020361545A1 (en) 2022-05-26
DE102019215585B4 (de) 2022-02-17
EP4021483A1 (de) 2022-07-06
WO2021069740A1 (de) 2021-04-15
KR20220080144A (ko) 2022-06-14
CA3153898A1 (en) 2021-04-15
DE102019215585A1 (de) 2021-04-15
BR112022006877A2 (pt) 2022-07-05
IL292125A (en) 2022-06-01
MX2022004331A (es) 2022-05-30
JP2022552309A (ja) 2022-12-15

Similar Documents

Publication Publication Date Title
Parkman et al. Neurotrophin-3 improves functional constipation
AU2004216904B2 (en) Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
Karri et al. Practice patterns for spasticity management with phenol neurolysis
Lim et al. Effects of repetitive peripheral magnetic stimulation on patients with acute low back pain: a pilot study
Gil et al. Botulinum toxin type A for the treatment of gastroparesis in Parkinson’s disease patients
JP2007528352A5 (ja) 副鼻腔炎に関連する慢性の顔面痛および頭痛のボツリヌス毒素での治療
ÖzDEMIR et al. A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis
Kataoka et al. Effects of 3-dimensional conformal or intensity-modulated radiotherapy on dental pulp sensitivity during and after the treatment of oral or oropharyngeal malignancies
US11857568B2 (en) Treatment and prevention of Alzheimer's disease (AD)
CN114746107A (zh) 用于预防人腺体遭受放射损伤的方法
WO2015165964A1 (en) Treatment and prevention of alzheimer's disease (ad)
Fallico et al. A randomised placebo-controlled clinical trial on the efficacy of local lidocaine injections and oral citalopram for the treatment of complex regional pain syndrome
Zhang et al. Effect of Modified Pharyngeal Electrical Stimulation on Patients with Severe Chronic Neurogenic Dysphagia: A Single-Arm Prospective Study
Warner et al. Refractory pain management in amyloid-associated peripheral neuropathy
JP2022546622A (ja) 胃不全麻痺の治療に使用するための神経毒素組成物
Tysnes Treatment of sialorrhea in amyotrophic lateral sclerosis
Aziz et al. INTRA-ARTICULAR CORTICOSTEROIDS VERSUS PHYSIOTHERAPY IN THE MANAGEMENT OF ADHESIVE CAPSULITIS: Adhesive Capsulitis
Fatema et al. Study of radiation induced xerostomia in head and neck cancer in conformal versus conventional radiotherapy
RU2260430C1 (ru) Способ лечения больных диссеминированными формами рака предстательной железы
Rahman et al. Comparison of Meglumine Antimoniate and Miltefosine in Cutaneous Leishmaniasis
Sampson et al. CTNI-52. SURVIVAL OUTCOMES IN RECURRENT GLIOBLASTOMA (RGBM) PATIENTS TREATED WITH A SINGLE INTRA-TUMORAL ADMINISTRATION OF BIZAXOFUSP, AN IL-4R-TARGETING TOXIN, IN A PHASE IIB TRIAL
Priya et al. Study of adverse effects of vildagliptin and insulin treatment in diabetes mellitus patients
Abdel-Fadeel et al. Effectiveness of theta-burst and high-frequency transcranial magnetic stimulation in treatment of depression: a double-blinded sham-controlled trial
Yama et al. Unearthing what lies beneath: A case series of 2 patients with secondary trigeminal neuralgia
Kittichet et al. A real‐life experience of long‐term use of pilocarpine in irradiated head and neck cancer patients

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40077033

Country of ref document: HK